Health Condition 1: null- â?¢Patients diagnosed with advanced hormone sensitive prostate cancer and planned for palliative systemic chemohormonal therapy.
Conditions
Interventions
None listed
Sponsors
Tata Memorial Centre
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with advanced hormone sensitive prostate cancer and planned for palliative systemic chemohormonal therapy 2. Patients willing to provide written informed consent to participate in the study 3. Patients willing to receive the usual standard treatment, which is chemohormonal therapy
Exclusion criteria
Exclusion criteria: •Not willing for follow up •Not planned for systemic therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To identify the mutations in the 32 genes from Qiagen Prostate Cancer Gene Read DNA seq Targeted Panel and subtract these mutations from the background germline DNA (from buffy coat DNA).Timepoint: Two years | — |
Secondary
| Measure | Time frame |
|---|---|
| 2. To characterize these identified mutations. 3. To use these mutations in blood to monitor response to therapy. 4. To evaluate whether tumour burden relates quantitatively to ctDNA. 5. To use these markers (in a personalized patient specific manner) to monitor therapy and progression by quantifying the same mutations in peripheral blood. Timepoint: Two years | — |
Countries
India
Contacts
Public ContactDr Vanita Noronha
1107, HBB, Dept of Medical Oncology, Tata Memorial Hospital, Dr E. Borges Marg, Parel, Mumbai 400012
Outcome results
None listed